Overview |
bs-13274R-Cy5.5 |
GALNT13/GalNAc-T13 Polyclonal Antibody, Cy5.5 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Rat |
Human, Mouse, Dog, Cow, Sheep, Pig, Rabbit |
Specifications |
Cy5.5 |
Rabbit |
KLH conjugated synthetic peptide derived from human GALNT13/GalNAc-T13 |
351-450/556 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
114805 |
Cytoplasm, Cell membrane |
GalNAc T13; GalNAc transferase 13; N acetylgalactosaminyltransferase 13; Polypeptide GalNAc transferase 13; pp GaNTase 13; Protein UDP acetylgalactosaminyltransferase 13; UDP GalNAc:polypeptide N acetylgalactosaminyltransferase 13; UDP N acetyl alpha D galactosamine:polypeptide; GLT13_HUMAN. |
The UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes are substrate-specific proteins that catalyze the transfer of GalNAc (N-acetylgalactosamine) to serine and threonine residues onto various proteins, thereby initiating mucin-type O-linked glycosylation in the Golgi apparatus. GalNAc-T13 (Polypeptide N-acetylgalactosaminyltransferase 13), also known as UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13, is a 556 amino acid protein that displays much stronger enzymatic activity than GalNAc-1 towards GalNAc transfer to mucin peptides such as Muc5a and Muc7. The N-terminal domain is involved in substrate binding and manganese coordination, while the C-terminal domain is involved in UDP-Gal binding and catalytic reaction. With specific expression in the central nervous system, GalNAc-T13 may be responsible for the synthesis of Tn antigen in neuronal cells, which is a universal carcinoma marker on malignant cells. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |